Sovran Advisors, LLC Summit Therapeutics Inc. Transaction History
Sovran Advisors, LLC
- $770 Billion
- Q1 2025
A detailed history of Sovran Advisors, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Sovran Advisors, LLC holds 146,528 shares of SMMT stock, worth $3.98 Million. This represents 0.47% of its overall portfolio holdings.
Number of Shares
146,528
Previous 117,174
25.05%
Holding current value
$3.98 Million
Previous $1.95 Billion
84.84%
% of portfolio
0.47%
Previous 0.28%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
230Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$663 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$317 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$214 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$178 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$152 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.46B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...